glp-1 receptor agonist transdermal patch How to Wear Patches: Current Status and Approved Alternatives GLP-1 Patches: What are They,

Where to learn more For clinicians: seek continuing education on metabolic medicine, peptide pharmacology, and gutbrain interactions

Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K (2009)

Randomization was conducted using an interactive web response system, assigning participants in a 6:1 ratio to one of several treatment arms: once-weekly subcutaneous Cagrilintide administered in doses of 0.3, 0.6, 1.2, 2.4, or 4.5 mg, once-daily liraglutide 3.0 mg, or a volume-matched placebo

These areas have higher concentrations of beta-3 adrenergic receptors, which are the primary target of the peptides mechanism